(SeaPRwire) – By: Oliver Hawthorne
UiPath beat revenue estimates. It matched earnings. It raised full-year guidance. The stock fell 16 percent. That sequence looks broken on the surface. The market is not confused. It is repricing the entire automation category. Enterprise buyers are stuck between traditional RPA contracts and AI-native automation. UiPath says its large deals now carry AI. That language is everywhere in the earnings call. But the billings line missed. Billings are the closest thing to real demand. They tell you whether buyers are signing enough new work. They did not sign enough. The anxiety is not about one quarter. It is about a structural shift. A 12 percent grower does not command an AI premium when faster software names exist. The old RPA story sold cost takeout. The AI story sells autonomous work. Somewhere between those two stories, UiPath must prove it owns the transition. So far, the proof is thin. Investors treated a beat as a legacy software event. That is the real damage. The market no longer believes the AI narrative. It wants evidence. This quarter did not provide it.
UiPath reported Q2 fiscal 2027 revenue of $410.3 million. That was up 13.3 percent year over year. Wall Street expected $397.8 million. Non-GAAP earnings per share came in at $0.15. That matched estimates. Billings landed at $375.5 million. That was a slight miss. Management pointed to longer customer decision-making cycles. Enterprises are weighing traditional automation against AI-driven automation. Annual recurring revenue grew 12 percent to $1.938 billion. The company posted its fourth straight quarter of GAAP profitability. It raised its full-year revenue forecast to $1.789 billion to $1.794 billion. It guided for roughly $445 million in non-GAAP operating income. Q3 revenue guidance came in at $440 million to $445 million. That was slightly above consensus. Investors had already priced in something bigger. The stock had gained roughly 9 percent in the previous eight days. On the morning after earnings, it opened at $16.24. The prior close was $18.22. It last traded near $15.12. That put the stock 21.6 percent below its 52-week high of $19.29. That high was hit in December 2025. CEO Daniel Dines said 18 of the top 20 deals this quarter included AI. He framed the company as a beneficiary of enterprise AI adoption. The market still sold. New CFO Hitesh Ramani described guidance as prudent. He cited macroeconomic variability and shifting customer adoption patterns. Analysts responded with small target bumps. BMO moved from $13 to $18 with a Market Perform rating. Wells Fargo went from $13 to $15 with Equal Weight. RBC moved from $15 to $17 at Sector Perform. DA Davidson raised from $12 to $16 at Neutral. TD Cowen raised from $13 to $16 at Hold. Of 19 analysts covering the stock, 16 rate it Hold. Two rate it Buy. One rates it Sell. The consensus price target is $15.73. That is barely above where the stock traded after the drop. Dines sold 1.4 million shares on August 19. The average price was $16.07. The transaction was worth over $22.5 million. He still holds more than 26 million shares. State Street, Morgan Stanley, and AQR Capital increased positions. Institutions now own 62.5 percent of the stock. PATH is down 4.8 percent year to date. A $1,000 investment five years ago would be worth roughly $242 today.
The commercial loop is unforgiving. UiPath sells automation capacity. Enterprises pay when automation becomes embedded in cost structures. That purchase is being delayed. Billings lead revenue by a quarter or two. A billings miss now creates softer revenue later. Management can raise full-year guidance on the back of existing ARR. But ARR growth sits at 12 percent. That is not an acceleration story. The AI inclusion figure from Dines is telling. Eighteen of twenty top deals included AI. That means the largest customers are testing AI. It does not mean they are expanding contract values. Inclusion can be a feature checkbox. It can also be a defensive retention move. If customers demand AI without spending more, the margin story weakens. The stock has now given up most of its recent gains. Analyst price targets moved up only slightly. The CEO sold just above current levels. Institutional accumulation offers some comfort. It can also be passive index buying. None of this resolves the core issue. The market is no longer valuing UiPath as an AI growth asset. It is valuing it as a cash-generating legacy automation tool. That re-rating can be rational. The company is profitable. It is not growing fast enough to command a premium. Buying this dip is not a value trade. It is a bet that enterprise decision cycles shorten. The billings number does not support that bet. I would rather wait for evidence. A quarter or two of billings growth above ARR growth would change the picture. Right now, management’s own guidance is prudent. The analyst consensus is a Hold. The CEO sold. That is not a setup for a fast rebound. Until billings re-accelerate, the 16 percent drop is not a buying opportunity. It is a correction to a more honest multiple.
Author bio: Oliver Hawthorne, Principal Correspondent at an international technology review, has covered enterprise software, automation, and AI infrastructure for over a decade, writing on the commercial and technical shifts inside large software vendors.